Table I.

The major possible MMP targeting treatments for osteoarthritis and rheumatoid arthritis

Osteoarthritis		Rheumatoid arthritis
Reference	Treatment	Reference	Treatment
Favero et al. (2019) [23]	TIMPs employment	Aihaiti et al. (2021) [72]	Naringin administration
Zeng et al. (2019) [26]	FOXM1 knockdown	Chen et al. (2019) [73]	Taraxasterol administration
Yang et al. (2018) [27]	IRF-8 knockdown	Nachvak et al. (2019) [74]	CoQ10 supplementation
Jiang et al.(2017) [28]	BRD4 inhibition by JQ1	Mirtaheri et al. (2022) [75]	SCC tea consumption
Qu et al. (2018) [43]	Ghrelin administration	Liu et al. (2019) [77]	PARP2 inhibition by miRNA-125
Inagaki et al. (2017) [44]	3-B2 in combination with low-dose betamethasone
Gao et al. (2020) [47]	Intra-articular injection of hyaluronic acid with iron-glutathione complex
An et al. (2020) [51] Li et al. (2019) [52] Bai et al. (2019) [53]	miRNA knockdown – miRNA-203a, miRNA-103, miRNA-122
Lei et al. (2019) [55] Zhao et al. (2018) [56]	lnRNA – miRNA-16-5p suppression via SNHG1, PVT1 suppression

BRD4 – bromodomain-containing protein 4, 3-B2 – 2-(8-methoxy-2-methyl-4-oxoquinolin-1(4H)-yl)-N-(3-methoxyphenyl) acetamide, 10FOXM1 – forkhead box M1, CoQ10 coenzyme – Q10, IRF-8 – interferon regulatory factor-8, PARP2 – poly(ADP-ribose) polymerase 2, PVT1 – plasmacytoma variant translocation 1, SCC – Stachys schtschegleevii, SNHG1 – small nucleolar RNA host gene 1, TIMPs – tissue inhibitors of metalloproteinases.